NewAmsterdam Pharma Company announced the appointment of Janneke van der Kamp as an independent director to its Board of Directors. van der Kamp currently serves as Chief Commercial Officer and member of the Executive Board of Grunenthal, a global leader in pain management, where she is responsible for global commercial strategy and execution.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NAMS:
- NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
- NewAmsterdam expects cash to fund operations through 2026
- NewAmsterdam reports 2022 EPS (EUR 0.96) vs. (EUR 1.19) last year
- NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update
- NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference